Conference
Earn CE
Free Samples
Magazine
Subscribe
Videos
Solutions Lab
Macro/Op-Ed
Practice
Science & Tech
Money
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Dental Market Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Denali Therapeutics Inc
(NQ:
DNLI
)
24.44
+0.04 (+0.16%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 30, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Denali Therapeutics Inc
< Previous
1
2
3
4
Next >
Benzinga's Top Ratings Upgrades, Downgrades For September 6, 2023
September 06, 2023
Via
Benzinga
Analyst Expectations for Denali Therapeutics's Future
August 31, 2023
Via
Benzinga
Denali Therapeutics Announces New Interim Data from Phase 1/2 Study of DNL310 (ETV:IDS) in MPS II (Hunter Syndrome) at SSIEM 2023
August 30, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Where Denali Therapeutics Stands With Analysts
August 10, 2023
Via
Benzinga
Denali Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights
August 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Cash In on the Longevity Boom: 3 Biotech Stocks to Buy Now
June 29, 2023
With longevity back in the news, many investors are wondering which biotech stocks to buy to best cash in on the growing trend.
Via
InvestorPlace
Analyst Expectations for Denali Therapeutics's Future
June 21, 2023
Within the last quarter, Denali Therapeutics (NASDAQ:DNLI) has observed the following analyst ratings:
Via
Benzinga
Denali Says Hunter Syndrome Candidate Lowers Disease-Associated Biomarker
June 20, 2023
Denali Therapeutics Inc (NASDAQ: DNLI) announced new interim results from the ongoing open-label, single-arm Phase 1/2 study of DNL310 IDS in children with
Via
Benzinga
Denali Therapeutics Announces Robust Reduction in Neurofilament Light (NfL) with DNL310 (ETV:IDS) Treatment in MPS II (Hunter Syndrome)
June 20, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Why Shares of Denali Therapeutics Are Up Monday
May 15, 2023
Analysts maintained their buy ratings on the clinical-stage biotech company.
Via
The Motley Fool
Biogen and Denali Realign Parkinson's Disease Research Priorities Amidst R&D Restructure
June 05, 2023
Via
Benzinga
Analysts Say These 2 Mid-Cap Biotechs Have 2x Potential
May 18, 2023
These two mid-cap biotech companies are relatively established in their fields — but according to analysts, still have significant upside.
Via
MarketBeat
Exposures
Product Safety
Denali Therapeutics Reports First Quarter 2023 Financial Results and Business Highlights
May 08, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Biogen Moves Deeper In Alzheimer's With Denali
April 14, 2023
Biogen exercised their rights to a Denali Alzheimer's drug. What does this mean longer term to the field and the companies?
Via
Talk Markets
Where Denali Therapeutics Stands With Analysts
April 12, 2023
Via
Benzinga
Where Denali Therapeutics Stands With Analysts
March 02, 2023
Via
Benzinga
Expert Ratings for Denali Therapeutics
January 30, 2023
Via
Benzinga
Biogen Exercises Option with Denali to Develop and Commercialize Antibody Transport Vehicle Program Targeting Amyloid Beta
April 12, 2023
Program uses Denali’s Antibody Transport Vehicle (ATV) technology to cross the blood-brain barrier (BBB) and aims to increase target engagement
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces New DNL343 (eIF2B Agonist) Phase 1b Data in ALS To Be Presented at the Upcoming AAN Annual Meeting
April 10, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results and Business Highlights
February 27, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Reveals New Interim Data From Early-Stage Hunter Syndrome Study
February 23, 2023
Via
Benzinga
Denali Therapeutics Announces New Interim Data from DNL310 Phase 1/2 Study for MPS II and DNL126 Preclinical Data for MPS IIIA at WORLDSymposium™
February 22, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
3 More Mid-Cap Biotechs The Street Sees Doubling
February 22, 2023
According to Wall Street research groups, these three mid-cap biotechs have 2x potential. It’s for the investor to decide if the upside justifies the risk.
Via
MarketBeat
Denali Therapeutics Announces Presentations on Enzyme Transport Vehicle (ETV) Development Programs for MPS Diseases at the Upcoming WORLDSymposium™
February 15, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For January 30, 2023
January 30, 2023
Via
Benzinga
Denali Therapeutics Announces Achievement of RIPK1 Milestone for Phase 2 Clinical Trial Initiation in Multiple Sclerosis by Sanofi
January 25, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces Key Anticipated 2023 Milestones for Its Therapeutic Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 09, 2023
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Denali Therapeutics Announces DNL343 Interim Phase 1b Data in ALS and Entry into the HEALEY ALS Platform Trial
December 05, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
Benzinga's Top Ratings Upgrades, Downgrades For December 5, 2022
December 05, 2022
Via
Benzinga
Denali Therapeutics Reports Third Quarter 2022 Financial Results and Business Highlights
November 03, 2022
From
Denali Therapeutics Inc.
Via
GlobeNewswire
< Previous
1
2
3
4
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.